Abstract
Background Alzheimer's disease (AD) genetic susceptibility and disease-associated transcriptional changes are typically studied separately. Whether genetically inferred molecular mechanisms converge with transcriptional changes observed in post-mortem brain tissue remains unclear. Methods Cell-type-specific AD differential expression signatures were generated from five independent single-cell transcriptomic studies comprising over two million brain cells. In parallel, polygenic risk score (PGS)-associated expression signatures were inferred across 3,202 individuals using GTEx eQTL effect estimates. Both representations were compared at the individual gene, pathway, and drug-perturbational levels using large-scale perturbational profiles from Connectivity Map (CMap) and LINCS resources. Results AD single-cell signatures exhibited substantial reproducibility across cell types and correlated positively with bulk-brain pathology signatures. Genetically inferred signatures showed minimal concordance with disease-derived profiles at the level of individual genes and biological pathways. In contrast, there was a positive association when projecting both signatures onto drug-response space. Vasodilators, antihypertensives, and metabolic agents were enriched among compounds showing consistent reversal signatures across both disease representation. Conclusions In the present analysis, genetic risk and end-stage AD pathology are largely decoupled at the level of individual genes and pathways but converge on a shared, pharmacologically modifiable response landscape. This convergence is consistent with biological mechanisms linked to established vascular and metabolic dementia risk factors, suggesting perturbational profiling as a potential framework for future therapeutic investigation rather than a basis for immediate drug prioritisation.